Temsirolimus
20 interactions 1 explained in plain EnglishTemsirolimus is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney). Temsirolimus is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that tells the cancer cells to multiply. This may help slow the growth of tumors. Read the full Temsirolimus drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Temsirolimus Lisinopril Prinivil Explained Increased risk of angioedema Details Temsirolimus Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Temsirolimus Benazepril Lotensin Increased risk of angioedema Details Temsirolimus Captopril Capoten® Increased risk of angioedema Details Temsirolimus Enalapril Epaned Increased risk of angioedema Details Temsirolimus Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Temsirolimus Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Temsirolimus Fosinopril Monopril® Increased risk of angioedema Details Temsirolimus Ketoconazole Topical Extina® Foam Increased exposure and maximum concentration of sirolimus, the active metabolite of temsirolimus Details Temsirolimus Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Temsirolimus Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Temsirolimus Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Temsirolimus Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Temsirolimus Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Temsirolimus Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Temsirolimus Moexipril Univasc® Increased risk of angioedema Details Temsirolimus Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Temsirolimus Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Temsirolimus Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Temsirolimus Perindopril Aceon Increased risk of angioedema DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist